Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Positive Technologies' RAS profits quadrupled in Q1

4/4/23 POSI

M.Video reported for 2022 according to RAS

4/3/23 MVID

Sistema reported for 2022 according to RAS

4/3/23 AFKS

Perm Power Supply Company reported for 2022 according to RAS

4/3/23 PMSB

Donskoy Radiodevay Plant reported for 2022 according to RAS

4/3/23 DZRD

Rosinter Restaurants Holding reports for 2022 according to RAS

4/3/23 ROST

Novatek wants to increase LNG transshipment in Murmansk

4/3/23 NVTK

Rosneft supplies oil to India with a price link to the Asian benchmark Dubai

4/3/23 ROSN

First floating LNG plant to depart for Yamal this summer

4/3/23 NVTK

Lukoil's RAS profit in 2022 increased by 24%

4/3/23 LKOH